

1645
5/105

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(To be used for all correspondence
after initial filing)

Application Number	10/099,926
Filing Date	March 14, 2002
First Named Inventor	Gordon E. King
Group Art Unit	1645
Examiner Name	
Attorney Docket No.	210121.547C2

RECEIVED

JUN 19 2002

ENCLOSURES (check all that apply)



TECH CENTER 1600/2000

- | | | |
|---|---|--|
| <input type="checkbox"/> Fee Transmittal Form
<input type="checkbox"/> Fee Attached
<input type="checkbox"/> Amendment/Response
<input type="checkbox"/> After Final
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Extension of Time Request
<input type="checkbox"/> Express Abandonment Request
<input checked="" type="checkbox"/> Information Disclosure Statement; Form PTO-1449
<input checked="" type="checkbox"/> Cited References (6)
<input type="checkbox"/> Certified Copy of Priority Document(s)
<input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53
<input type="checkbox"/> Response to Missing Parts/Incomplete Application | <input type="checkbox"/> Assignment Papers (for an Application)
<input type="checkbox"/> Drawing(s)
<input type="checkbox"/> Request for Corrected Filing Receipt
<input type="checkbox"/> Licensing-related Papers
<input type="checkbox"/> Petition
<input type="checkbox"/> Petition to Convert to a Provisional Application
<input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address
<input type="checkbox"/> Declaration
<input type="checkbox"/> Statement under 37 CFR 3.73(b)
<input type="checkbox"/> Terminal Disclaimer
<input type="checkbox"/> Small Entity Statement
<input type="checkbox"/> Request for Refund | <input type="checkbox"/> CD(s), Number of CD(s) _____
<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Return Receipt Postcard
<input type="checkbox"/> Additional Enclosure(s) (please identify below):

_____ |
|---|---|--|


Remarks


SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Individual Name	Julie A. Urvater, Ph.D. 50,461	 00500 PATENT TRADEMARK OFFICE
Signature		
Date	6-12-02	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date specified below.

Typed or printed name	Monica Steinborn	
Signature		Date: 6/13/02



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUN 19 2002

TECH CENTER 1600/2300

Applicants : Gordon E. King et al.
Application No. : 10/099,926
Filed : March 14, 2002
For : COMPOSITIONS AND METHODS FOR THE THERAPY AND
DIAGNOSIS OF COLON CANCER

Art Unit : 1645
Docket No. : 210121.547C2

Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT


Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO-1449 (copies of the cited references are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



Julie A. Urvater, Ph.D.
Registration No. 50,461


JAU:mls

Enclosures:

Postcard
Form PTO/SB/21
Form PTO-1449
Cited References (6)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

D:\NrPortbl\iManage\MONICAS\292532_1.DOC

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.547C2APPLICATION NO.
10/099,926

Sheet 1 of 1

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Gordon E. King et al.

FILING DATE

March 14, 2002

GROUP ART UNIT
1645

JUN 19 2002

RECEIVED

U.S. PATENT DOCUMENTS

TECH CENTER 1600/2900

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AG	WO 00/37643	06/29/00	WIPO		
	AH	WO 98/53319	11/26/98	WIPO		
	AI					
	AJ					
	AK					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AL	Database EMBL20 May 1999 (1999-05-20), "Homo sapiens mRNA; cDNA DKFZp586A1123 (from clone DKFZp586A1123); partial cds," Database accession no. AL050181.
AM	Frigerio, J.M. et al, "Analysis of 2166 clones from a human colorectal cancer cDNA library by partial sequencing," <i>Human Molecular Genetics</i> 4(1):37-43, 1995.
AN	Schena et al., "Quantitative monitoring of gene expression patterns with a complementary DNA microarray," <i>Science</i> 270:467-470, October 20, 1995.
AO	Yee et al., "Isolation of tyrosinase-specific CD8 ⁺ and CD4 ⁺ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus," <i>The Journal of Immunology</i> 157:4079-4086, 1996.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).